The purpose of this observational post-marketing registry will be to collect and analyze safety, effectiveness, and quality of life outcomes, during and after treatment with the Surpass Flow Diverter. Health Economics assessments (cost data) will also be collected and analyzed.
This will be a prospective, observational, multi-center, single-arm, post-marketing, international registry with consecutive enrollment of a minimum of 150 patients treated with the Surpass Flow Diverter in accordance with the standard of care at up to 30 registry sites.
Study Type
OBSERVATIONAL
Enrollment
150
Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
AZ groeninge
Kortrijk, Belgium
Helsinki University Hospital
Helsinki, Finland
Primary effectiveness based on the proportion of patients with 100% aneurysm occlusion
The proportion of patients with 100% aneurysm occlusion, based on an assessment of each patient's imaging at 12 months (± 180 days) post-procedure, and stratified across four aneurysm categories.
Time frame: 12 months
Technical success assessed by deployment of the device with complete coverage of the aneurysm neck
Successful deployment of the device with complete coverage of the aneurysm neck.
Time frame: Peri-procedural
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Turun yliopistollinen keskussairaala
Turku, Finland
Hopital Jean Minjoz
Besançon, France
APHP - Kremlin Bicêtre
Le Kremlin-Bicêtre, France
Fondation Rothschild
Paris, France
Hopital Bretonneau
Tours, France
Freiburg University Hospital
Freiburg im Breisgau, Germany
Klinikum Kassel
Kassel, Germany
Universitätsmedizin Mannheim
Mannheim, Germany
...and 9 more locations